Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017;10(3):207-215.
doi: 10.1159/000471488. Epub 2017 Jun 1.

The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function

Affiliations
Review

The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function

Gijs H Goossens. Obes Facts. 2017.

Abstract

The current obesity epidemic poses a major public health issue since obesity predisposes towards several chronic diseases. BMI and total adiposity are positively correlated with cardiometabolic disease risk at the population level. However, body fat distribution and an impaired adipose tissue function, rather than total fat mass, better predict insulin resistance and related complications at the individual level. Adipose tissue dysfunction is determined by an impaired adipose tissue expandability, adipocyte hypertrophy, altered lipid metabolism, and local inflammation. Recent human studies suggest that adipose tissue oxygenation may be a key factor herein. A subgroup of obese individuals - the 'metabolically healthy obese' (MHO) - have a better adipose tissue function, less ectopic fat storage, and are more insulin sensitive than obese metabolically unhealthy persons, emphasizing the central role of adipose tissue function in metabolic health. However, controversy has surrounded the idea that metabolically healthy obesity may be considered really healthy since MHO individuals are at increased (cardio)metabolic disease risk and may have a lower quality of life than normal weight subjects due to other comorbidities. Detailed metabolic phenotyping of obese persons will be invaluable in understanding the pathophysiology of metabolic disturbances, and is needed to identify high-risk individuals or subgroups, thereby paving the way for optimization of prevention and treatment strategies to combat cardiometabolic diseases.

Keywords: Adipose tissue function; Body fat; Metabolic health; Obesity; Oxygen.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Differences in adipose tissue function and body fat distribution between MHO and metabolically unhealthy obese individuals. Expansion of adipose tissue does not necessarily translate into metabolic abnormalities. A subgroup of individuals with obesity, referred to as MHO individuals, is relatively protected against the development of cardiometabolic diseases as compared to metabolically unhealthy obese subjects. Emerging evidence suggests that alterations in adipose tissue function and body fat distribution are key factors underlying the metabolically unhealthy obese phenotype. Metabolically unhealthy obese individuals are characterized by lower subcutaneous fat mass, adipocyte hypertrophy, a pro-inflammatory adipose tissue phenotype and an impaired fat storage capacity of adipose tissue, which may result in ectopic fat deposition (i.e., more visceral fat, lipid accumulation in the liver and skeletal muscle) and inflammation in visceral adipose tissue, thereby contributing to the development of insulin resistance and chronic cardiometabolic diseases. ASAT = abdominal subcutaneous adipose tissue; FSAT = femoral subcutaneous adipose tissue; VAT = visceral adipose tissue.

Similar articles

Cited by

References

    1. Kopelman PG. Obesity as a medical problem. Nature. 2000;404:635–643. - PubMed
    1. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46:3–19. - PubMed
    1. Bergman RN, Ader M, Huecking K, Van Citters G. Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes. 2002;51(suppl 1):S212–220. - PubMed
    1. Blundell JE, Dulloo AG, Salvador J, Fruhbeck G. Beyond BMI - phenotyping the obesities. Obes Facts. 2014;7:322–328. - PMC - PubMed
    1. Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care. 2008;11:693–700. - PMC - PubMed